PGEN
Precigen, Inc.
$5.32
-0.21 (-3.80%)
At close · Jul 10
View the 10-Q filed May 13, 2026
Customer concentration
— top 4 customers 49.9% of revenue
4 customers — 49.9% of revenue (the three months ended March 31, 2025)
“For the three months ended March 31, 2025, four customers accounted for 49.9% of total condensed consolidated revenues.”
Market Cap
$1.90B
Shares
356,510,980
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.32
Open$5.50
Day$5.17–5.50
52W$1.47–6.04
Avg vol 30d5.1M
Short int44.2M · 12.4% float · 7.6d
Short vol63%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
Next earnings call
Oct 18, 2026
Est · unconfirmed
· in 14 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+29%
above
Price vs 50-day avg
+16%
above
RSI (14)
56
neutral
MACD trend
Negative
52-week position
84%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+37%
trailing
6-month return
+29%
trailing
YTD return
+27%
this year
Relative strength
+19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Distributing
7 of 204 funds reported for Jun 30 · net -24.9K sh shares · +1 new
Insider flow
Distributing
Net -$1.1M over 90 days · 100% sells
Short interest
Rising
12.40% of float · ▲ +2.0% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
204 holders — near 3-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+21%
Y/Y
EPS growth
−191%
Y/Y
Free cash flow
$-89.8M
Balance sheet
$62.9M
net debt
Quant / Vol
risk profile
Volatility
105%
annualized · 1-yr
Max drawdown
−41%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2025
Q1 2026
Revenues
Initiated
$18M
prior qtr $23.25M
midpoint −22.6% QoQ
2026
Revenue
Initiated
$18M
prior FY $9.68M
midpoint +85.9% Y/Y
Guided vs delivered
· last 1 settled
Revenues
Q1 2026
$23.25M
Beat +29.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+29%
Bullish
Price vs 50-day avg
+16%
Bullish
RSI (14)
56
Neutral
MACD trend
Negative
Bearish
52-week position
84%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Distributing
7 of 204 funds reported for Jun 30 · net -24.9K sh shares · +1 new
Insider flow
Distributing
Net -$1.1M over 90 days · 100% sells
Short interest
Rising
12.40% of float · ▲ +2.0% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
204 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $5 · 84%
52-wk high $6
vs 200-day avg +29%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| PAPZIMEOS net product revenue | $21.6M | Q1 FY2026 | — |
| Patient hub enrollment | 400 | Q1 FY2026 | — |
| Patient hub enrollment from community setting | 25% | Q1 FY2026 | — |
| Private health plan coverage (US lives) | 215M | Q1 FY2026 | — |
| Total estimated US lives with access to PAPZIMEOS | 297M | Q1 FY2026 | — |
| insured lives covered | 90% | Q1 2026 (as of today) call | — |
| patients registered | 400 | Q1 2026 (as of today) call | — |
| total lives covered through commercial, Medicare and Medicaid | 297M | Q1 2026 (as of today) call | — |
| PAPZIMEOS patient hub enrollment | 300 | to date | — |
| Payer coverage (lives) | 215M | to date | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PGEN
this stock
Precigen, Inc.
|
$1.90B | +27.3% | +21.0% | — | 12.4% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PGEN | -5.7% | +36.8% | +28.5% | -6.7% | +27.3% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -7.0% | +32.7% | +19.4% | -7.8% | +16.6% |